Navigation Links
Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
Date:5/22/2012

SUNNYVALE, Calif., May 22, 2012 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that clinical abstracts on Bruton's Tyrosine Kinase inhibitor, ibrutinib (formerly, PCI-32765) have been selected for oral presentations at the 17th Congress of the European Hematology Association (EHA), June 14-17, 2012 in Amsterdam, The Netherlands.

The update on data presented specifically includes: 1) updated safety and efficacy data, including progression free survival, from the phase Ib/II CLL single agent trial in relapsed or refractory and treatment naive patients (PCYC-1102-CA); 2) safety and efficacy data from the phase Ib CLL combination trial with bendamustine and rituximab in relapsed or refractory patients (PCYC-1108-CA). Pharmacyclics plans to issue a material update on the ibrutinib clinical development program and its results in a press release after the EHA oral presentations.

Oral Presentation at EHA, Amsterdam, The Netherlands (June 14-17, 2012)
Date/Time: Saturday, June 16, 2012; 8:00 AM – 8:15 AM CET
Location: Elicium 1
Abstract # 1970: The Bruton's Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) is Highly Active and Tolerable in Relapsed or Refractory and Treatment Naive Chronic Lymphocytic Leukemia Patients, Updated Results of a Phase Ib/II Study.
Dr. Susan M. O'Brien et al. MD Anderson Cancer Center, Houston, Texas.

Oral Presentation at EHA, Amsterdam, The Netherlands (June 14-17, 2012)
Date/Time: Saturday, June 16, 2012; 8:15 AM – 8:30 AM CET
Location: Elicium 1
Abstract # 1590: Combination of the Bruton's tyrosine kinase inhibitor PCI-32765 with bendamustine/rituximab in patients with relapsed/refractory chronic lymphocytic leukemia: Interim results of a phase Ib/II study.
Dr. Jennifer Brown et al. Dana-Farber Cancer Institute, Boston, Massachusetts.

Ibrutinib is an oral
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib (PCI-32765) at the 2012 Annual Meeting of the American Society of Clinical Oncology
2. Pharmacyclics to Host a Conference Call on March 15, 2012 to Discuss Second Quarter Fiscal 2012 Financial and Operational Results
3. Pharmacyclics Inc. Receives Issue Notice of Significant Brutons Tyrosine Kinase (BTK) Patent
4. Pharmacyclics Forms Pact to Develop and Commercialize PCI-32765 for Hematologic Cancers with Janssen Biotech, Inc.
5. Pharmacyclics Reports Fiscal 2012 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 53rd American Society of Hematology Annual Meeting
6. Pharmacyclics Reports Financial Results and Recent Developments for Fiscal Year and Fourth Quarter 2011 - Conference Call Set for Today at 4:30 PM EDT
7. Pharmacyclics Announces Date of Fiscal Year End 2011 Financial Results and Conference Call
8. Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765
9. Pharmacyclics Announces Oral Presentations and Clinical Update at Upcoming Medical Meetings
10. Pharmacyclics to Announce Third Quarter Fiscal 2011 Results and Host a Conference Call on May 4, 2011
11. Pharmacyclics to Announce Second Quarter Fiscal 2011 Results and Host a Conference Call on February 4, 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... , August 27, 2014 ... Market By Products (Dental Radiology, CAD/CAM, Dental Chairs, Dental Lasers), Current ... by MarketsandMarkets, the global Dental Equipment Market is expected ... million in 2014, growing at a CAGR of ... 95 market data tables and 61 figures spread ...
(Date:8/27/2014)... Aug. 27, 2014 Pulse Systems, Inc. , ... Practice Management , and Revenue Cycle Management (RCM) ... practices performed by some RCM vendors, at UBM Medica,s ... on September 19-20, 2014.  A presenter ... in September with a new session encouraging practices to "Look ...
(Date:8/27/2014)... 2014 Sihuan Pharmaceutical Holdings Group Ltd. ... leading pharmaceutical company with the largest cardio-cerebral vascular ... prescription drug market, today announced the unaudited ... (collectively the "Group") for the six months ended ... HighlightsFor the Six months ended 30 JuneKey Income ...
Breaking Medicine Technology:Dental Equipment Market Worth $7,138.9 Million by 2019 2Dental Equipment Market Worth $7,138.9 Million by 2019 3Pulse Systems Presents the Truth about Revenue Cycle Management Services at Practice Rx 2Pulse Systems Presents the Truth about Revenue Cycle Management Services at Practice Rx 3Pulse Systems Presents the Truth about Revenue Cycle Management Services at Practice Rx 4Sihuan Pharmaceutical Announces 2014 Interim Results 2Sihuan Pharmaceutical Announces 2014 Interim Results 3Sihuan Pharmaceutical Announces 2014 Interim Results 4Sihuan Pharmaceutical Announces 2014 Interim Results 5Sihuan Pharmaceutical Announces 2014 Interim Results 6Sihuan Pharmaceutical Announces 2014 Interim Results 7
... 2012 Quest International, Inc., a leading global supplier ... announced today that is has contributed $5000 to the ... American Cancer Society Key Gala, that benefits the Boston ... on Thursday, March 29, 2012. "We are ...
... Access NOW! (PCPAN) coalition today applauded the United Mine Workers ... Express Scripts, Inc. (ESI) and Medco Health Solutions, two ... the Federal Trade Commission (FTC), the UMW said the ... union mine workers. UMW is a growing ...
Cached Medicine Technology:Quest International Donates $5000 to the American Cancer Society 2Nationwide Coalition Applauds United Mine Workers For Voicing Concern Over Proposed ESI/Medco Merger 2
(Date:8/27/2014)... WEDNESDAY, Aug. 27, 2014 (HealthDay News) -- A new ... an effective treatment for seniors with sleep apnea. ... obstructive sleep apnea, a condition in which the airway ... interrupted sleep that leads to daytime drowsiness. ... stream of air through a patient,s nose via a ...
(Date:8/27/2014)... from our parents shapes many aspects of our lives. ... epigenome that is set during development, but can be ... by those of our parents and grandparents. , The ... supporting proteins that determine whether genes are expressed or ... our own health, but also that it may be ...
(Date:8/27/2014)... Boston, MA (PRWEB) August 27, 2014 Tejal ... Patient Safety Foundation (NPSF) and the NPSF Lucian Leape ... announced in the August 25 issue of Modern Healthcare magazine. ... MD, PhD; and Andrew Sussman, MD, MBA; NPSF Lucian ... Gary Kaplan, MD, who is a member of both the ...
(Date:8/27/2014)... August 27, 2014 Scientists at The Scripps ... a specific signaling pathway can be associated with alcohol ... a gene, called neurofibromatosis type 1 (Nf1), which TSRI ... The new research shows Nf1 regulates gamma-aminobutyric acid (GABA), ... relaxation. , "This novel and seminal study provides ...
(Date:8/27/2014)... Georgia State University’s Center for Leadership in Disability ... the Maternal and Child Health Bureau of the ... of the Autism Plan for Georgia, aimed at ... spectrum disorder. , In preparing for this project, ... of key stakeholders from across Georgia. The resulting ...
Breaking Medicine News(10 mins):Health News:Sleep Apnea Treatment Helps Seniors, Study Finds 2Health News:Scientists map the 'editing marks' on fly, worm, human genomes 2Health News:Scientists map the 'editing marks' on fly, worm, human genomes 3Health News:Scientists map the 'editing marks' on fly, worm, human genomes 4Health News:NPSF President Among 100 Most Influential in Health Care 2Health News:NPSF President Among 100 Most Influential in Health Care 3Health News:Scripps Research Institute scientists link alcohol-dependence gene to neurotransmitter 2Health News:Center for Leadership in Disability Awarded $600,000 Grant to Improve Services for Georgia’s Children and Youth with Autism 2
... Adlyfe, a private company,developing novel diagnostic testing ... that it has appointed Roxanne Duan, Ph.D.,as Vice ... for overseeing,the Adlyfe,s Research efforts and will report ... to Adlyfe with nearly two decades of experience. ...
... 17 Symmetry Medical Inc.,(NYSE: SMA ), ... orthopedic,device industry and other medical markets, announced today ... http://www.symmetrymedical.com, which contains improved,user- friendly features. ... languages, provides easy to,find product information and a ...
... concludes, , , MONDAY, Sept. 17 (HealthDay News) -- ... asthma you develop, new research suggests. , The ... countries had more allergy-triggered asthma symptoms than did ... "The link between atopic sensitization and asthma symptoms ...
... YORK -- Before a new treatment becomes available, researchers ... in clinical research trials. But finding these patients is ... studies or unable to participate due do logistical hurdles. ... novel treatment approaches -- and beneficial new therapies take ...
... SAN DIEGO, Sept. 17 CryoCor, Inc. (Nasdaq:,CRYO), a ... announced today that Edward F. Brennan, President and Chief,Executive ... to present at the Maxim Group First Annual Growth ... at 10:00 a.m. ET at The Grand,Hyatt Hotel. ...
... address the nation,s largest public health challenges, including AIDS, should be ... ... plans, WASHINGTON, Sept. 17 ... next President to,commit to ending the AIDS epidemic in America. They ...
Cached Medicine News:Health News:Adlyfe Appoints Roxanne Duan as Vice President of Research 2Health News:Adlyfe Appoints Roxanne Duan as Vice President of Research 3Health News:Symmetry Medical Launches New Global Web site 2Health News:Symmetry Medical Launches New Global Web site 3Health News:Allergy-Induced Asthma More Common in Affluent Countries 2Health News:Allergy-Induced Asthma More Common in Affluent Countries 3Health News:IMPACT initiative looks to improve patient participation in clinical trials 2Health News:CryoCor to Present at Maxim Group First Annual Growth Conference in New York 2Health News:More Than 100 Organizations Call for a National AIDS Strategy to End the Epidemic in the United States 2Health News:More Than 100 Organizations Call for a National AIDS Strategy to End the Epidemic in the United States 3
... designed to give reliable performance for all mixing ... button, power supply socket and fuse holder are ... The speed knob is located on the bottom ... a minimum 950 rpm to a maximum of ...
ThermoPrep 3's two systems in "one" approach, its capability to accommodate up to two standard microplates and its user-selectable settings offers the versatility and throughput you need in today's l...
... only four-color, automated benchtop flow cytometry system ... sorting. Designed specifically to support a wide ... software instrument control, auto-sample loading, and push-button ... FACSCalibur is fully modular so it can ...
... cytometer especially suited for cell analysis ... CyFlow allows to analyze scatter signals ... fluorescence channels. Data acquisition, analysis, and ... built-in PC employing Partec DPAC software, ...
Medicine Products: